ARUP Laboratories' Ronald Weiss Wins Prestigious Governor's Medals for Science and Technology
17 mars 2015 14h22 HE
|
ARUP Laboratories
SALT LAKE CITY, March 17, 2015 (GLOBE NEWSWIRE) -- Eight Utah individuals, including ARUP Laboratories Ronald Weiss, MD, were awarded the annual Governor's Medals for Science and Technology -- Utah's...
Pre-Clinical Animal Pilot Study Shows Arch Therapeutics' AC5(TM) Compared Favorably Versus a Popular Hemostatic Agent
23 févr. 2015 08h57 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Feb 23, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ for use in bleeding during...
Nanomedicine: Nanotechnology, Biology, and Medicine Publishes Preclinical Data on Arch Therapeutics' AC5 Surgical Hemostatic Device(TM)
19 févr. 2015 08h56 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Feb 19, 2015) - Positive data from an independent third-party research group study sponsored by Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"),...
The British Standards Institution Classifies Arch Therapeutics' AC5(TM) as a Medical Device Within the European Union
17 févr. 2015 08h00 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Feb 17, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a medical device company and developer of the AC5 Surgical Hemostatic Device™...
Arch Therapeutics Obtains Additional Positive Results for AC5 Surgical Hemostatic Device(TM) in Preclinical Safety Study
13 janv. 2015 08h57 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Jan 13, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, obtained positive results when...
Arch Therapeutics Announces Positive Results for AC5 Surgical Hemostatic Device(TM) in Biochemical and Cell Function Safety Studies
06 janv. 2015 08h57 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Jan 6, 2015) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, obtained positive results...
Arch Therapeutics to Present at The Biotech Showcase(TM) 2015 Conference on January 14th 2015
17 déc. 2014 08h57 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Dec 17, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, announced that it would be...
Arch Therapeutics to Present at LD Micro Main Event on December 4th 2014
24 nov. 2014 16h00 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Nov 24, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, announced that it would be...
Arch Therapeutics Reports Positive Preclinical Data from Study of AC5 Surgical Hemostatic Device(TM) in Animals Treated with Brilinta(R) (ticagrelor)
18 nov. 2014 08h57 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Nov 18, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostat Device™, announced that an independent...
Arch Therapeutics Will Present at Two Investor Conferences in November
10 nov. 2014 08h57 HE
|
Arch Therapeutics, Inc.
WELLESLEY, MA--(Marketwired - Nov 10, 2014) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™, announced that it would be...